Synedgen uses glycochemistry to develop drugs that enhance and mimic the innate immune system, and its platform has produced five FDA 510(k)-cleared therapeutics, one OTC drug, one veterinary indexed drug, and an out-licensed Phase 2 program to Synspira for pulmonary complications of cystic fibrosis. Its lead development candidate is SYGN305 for gastrointestinal mucositis. The company has developed SynePure Wound Cleanser and Catasyn Advanced Technology Wound Hydrogel, both FDA 510(k)-cleared medical devices formulated with glycopolymers. Synedgen intends to commercialize SynePure and Catasyn and to run a randomized clinical trial comparing them with standard of care in partial-thickness (second-degree) burns. Development of the products has been funded by the Defense Health Agency (DHA) as well as the DARPA SBIR program. Synedgen has research and manufacturing facilities in Claremont, California. The company announced a combined $1 million DHA SBIR award plus additional DHA research funding to advance commercialization and the planned clinical program. Synedgen develops therapeutics using a glycochemistry platform, with a focus on wound care products Catasyn Advanced Technology Wound Hydrogel and SynePure Wound Cleanser. The company received $2.6 million in private financing to fund commercialization, final manufacturing, and indication-expansion efforts for those FDA 510(k)-cleared products. Catasyn has an OTC indication for minor skin wounds and a professional indication for partial-to-full-thickness dermal ulcers, surgical wounds, and certain burns; SynePure is cleared for wound irrigation in single- and multiple-use bottles and is designed for battlefield first-aid use. Development of both products was supported by U.S. Army and DARPA grants, and clinical trials are planned to raise their technological readiness level for broader Department of Defense adoption. Synedgen’s lead development candidate is SYGN305 for gastrointestinal mucositis, and the company’s platform has generated five FDA 510(k)-cleared therapeutics, one OTC drug, one veterinary indexed drug, and an out-licensed Phase 2 program to Synspira. Synedgen operates research and manufacturing facilities in Claremont, California.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2020